

-- 30. An isolated DNA molecule comprising an adenoviral inverted terminal repeat (ITR), a packaging signal, a transcriptional control region, an effector or reporter gene, and either a genomic integration sequence or an episomal maintenance sequence, all operatively associated for generating an infectious, replication-defective recombinant adenoviral vector wherein the remaining portion of said DNA molecule does not encode an adenoviral protein. --

REMARKS


The amendments requested herein are fully supported by the specification as filed. The amendments are made without prejudice, disclaimer or presumption. The amendments herein are made merely to expedite prosecution of the instant application. Claims 1-29 are cancelled and claim 30 is pending.

CONCLUSION

Entry of the amendments and consideration of the remarks herein is earnestly solicited. The applicants urge the Patent Office to contact the undersigned at extension 2117 if the Patent Office believes this would expedite prosecution of the application. The Commissioner is authorized to credit any overpayment of fees or debit any underpayment of fees associated with this response to Deposit Account No. 13-2490. The applicants respectfully assert that the pending claim is allowable and request prompt issuance of a Notice of Allowance.

Respectfully submitted,

Date: January 8, 2002



Mark L. Chael, Ph.D.
Patent Agent
Reg. No. 44,601

McDonnell Boehnen Hulbert & Berghoff
300 South Wacker Drive, 32nd Floor
Chicago, Illinois 60606
Telephone: 312 913 0001
Facsimile: 312 913 0002